Processa Total Current Assets from 2010 to 2026
| PCSA Stock | USD 2.86 -0.02 -0.69% |
Total Current Assets | First Reported 2012-09-30 | Previous Quarter 7.2 M | Current Value 6.6 M | Quarterly Volatility 6.5 M |
Macro event markers
This statements view for Processa Pharmaceuticals organizes long-term performance signals with capital structure context. Key drivers include Interest Expense of 99.5 K, Selling General Administrative of 3 M or Total Revenue of 0.0 along with ratios such as Price To Sales Ratio of 198, Dividend Yield of 0.0 or PTB Ratio of 1.74. This view complements Processa Pharmaceuticals Valuation and Volatility modules.
Processa | Total Current Assets | Build AI portfolio with Processa Stock |
Analyzing Processa Pharmaceuticals's Total Current Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Current Assets has evolved provides context for assessing Processa Pharmaceuticals's current valuation and future prospects.
Latest Processa Pharmaceuticals' Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Processa Pharmaceuticals over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Processa Pharmaceuticals' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Processa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Processa Total Current Assets Regression Statistics
| Arithmetic Mean | 4,027,737 | |
| Geometric Mean | 1,749,044 | |
| Coefficient Of Variation | 134.33 | |
| Mean Deviation | 3,816,249 | |
| Median | 2,046,929 | |
| Standard Deviation | 5,410,282 | |
| Sample Variance | 29.3T | |
| Range | 18.2M | |
| R-Value | 0.31 | |
| Mean Square Error | 28.2T | |
| R-Squared | 0.1 | |
| Significance | 0.22 | |
| Slope | 333,901 | |
| Total Sum of Squares | 468.3T |
Processa Total Current Assets History
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. Liquidity and trading activity can influence how quickly new information is reflected in Processa Pharmaceuticals's price. Lower liquidity may increase execution variability. Processa Pharmaceuticals has a market cap of 6.53 M, ROE of -2.71%. 
Rifka Kats ยท Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Processa Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Processa (USA Stocks:PCSA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Processa Pharmaceuticals is covered by 1 analyst. Representative analyst firms may include RBC Capital Markets, Barclays, HSBC Global Research, Wells Fargo Securities, Bank of America Securities, among others. Updates may occur throughout the day.
Processa Stock is Curated By:
Rifka Kats ยท Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Processa Stock Analysis
Reviewing Processa Pharmaceuticals commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Processa Pharmaceuticals' operating context. Outlined below are key reports that provide context for Processa Pharmaceuticals Stock:Compare Processa Pharmaceuticals against competitors using Processa Pharmaceuticals Correlation. This adds peer-relative context. To understand the process of investing in Processa Stock, visit our How to Invest in Processa Pharmaceuticals guide.Analysis related to Processa Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Investors evaluate Processa Pharmaceuticals using market value and book value, each describing different facets of the business. Processa Pharmaceuticals' market capitalization is 6.53 M. A P/B ratio of 1.12 indicates the market values Processa Pharmaceuticals above its accounting book value. Enterprise value stands at 216.99 K. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Processa Pharmaceuticals are related but not identical, and they can diverge across cycles. For Processa Pharmaceuticals, key inputs include a P/B ratio of 1.12, and ROE of -2.71%. Market price reflects the current exchange level formed by active bids and offers.